nitrendipine has been researched along with Bright Disease in 4 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test whether calcium entry blockers (CEB) affect the course of progressive renal disease, we examined a standardized model of antiglomerular basement membrane glomerulonephritis (GN) in rats with and without oral administration of the CEB, nitrendipine (Nit)." | 7.67 | Effects of nitrendipine on the course of experimental immunologic glomerulonephritis. ( McKenzie, DE; Sterzel, RB, 1987) |
| "To test whether calcium entry blockers (CEB) affect the course of progressive renal disease, we examined a standardized model of antiglomerular basement membrane glomerulonephritis (GN) in rats with and without oral administration of the CEB, nitrendipine (Nit)." | 3.67 | Effects of nitrendipine on the course of experimental immunologic glomerulonephritis. ( McKenzie, DE; Sterzel, RB, 1987) |
| "Chronic administration of nitrendipine (N) prevented the development of serious renal damage in Wistar rats with experimental glomerulonephritis." | 3.67 | Comparison of BAY e 5009 (nitrendipine) with dihydralazine in Wistar rats with experimentally induced nephritis. ( Mohácsi, G; Sonkodi, S, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Remuzzi, A | 1 |
| Imberti, O | 1 |
| Puntorieri, S | 1 |
| Malanchini, B | 1 |
| Macconi, D | 1 |
| Magrini, L | 1 |
| Bertani, T | 1 |
| Remuzzi, G | 1 |
| Mohácsi, G | 2 |
| Abrahám, G | 1 |
| Sonkodi, S | 2 |
| Sterzel, RB | 1 |
| McKenzie, DE | 1 |
4 other studies available for nitrendipine and Bright Disease
| Article | Year |
|---|---|
Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats.
Topics: Alpha-Globulins; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Electrop | 1994 |
Effects of nitrendipine and captopril on nephritic rats.
Topics: Animals; Captopril; Glomerulonephritis; Male; Nitrendipine; Rats; Rats, Inbred Strains | 1990 |
Effects of nitrendipine on the course of experimental immunologic glomerulonephritis.
Topics: Animals; Basement Membrane; Blood Pressure; Fluorescent Antibody Technique; Glomerulonephritis; Kidn | 1987 |
Comparison of BAY e 5009 (nitrendipine) with dihydralazine in Wistar rats with experimentally induced nephritis.
Topics: Animals; Antibodies; Basement Membrane; Blood Pressure; Dihydralazine; Glomerulonephritis; Hydralazi | 1988 |